Physiologically based pharmacokinetic modeling is a mathematical approach that simulates the concentration profiles of a drug in blood and tissues based on physiological, physicochemical, and biochemical parameters. The abbreviation PBPK stands for Physiologically Based Pharmacokinetic Modeling. Unlike general modeling approaches, a PBPK model explicitly represents absorption, distribution, metabolism, and elimination in their interaction with the human organism.<\/p>\n
The EMA defines a PBPK model as a mathematical model that simulates drug concentrations over time in tissue and blood. System-dependent components include anatomical representation, organ blood flow, tissue composition, and the abundance of enzymes and transporters in the simulated population. Drug-specific parameters include, among others, physicochemical properties, in vitro and in vivo ADME data, and pharmacokinetic characteristics.<\/p>\n
The model structure defines the compartments, absorption assumptions, and organ distribution models. A computer program solves the underlying equations numerically but is not the PBPK model itself. This distinction is regulatorily significant: the platform, version, system data, drug file, and the specific intended use must each be described in such a way that predictions can be reconstructed and their limitations identified.<\/p>\n
The reliability of a drug model is assessed by how well relevant characteristics have been tested against in vivo pharmacokinetics and whether appropriate sensitivity and uncertainty analyses are available. A sensitivity analysis quantitatively shows how changes or uncertainties in input parameters alter the model result. It makes it visible whether a prediction depends particularly strongly on an enzyme value or a distribution parameter, for example.<\/p>\n
The EMA understands the qualification of a PBPK platform as building confidence for a specific scenario and a specific purpose based on scientific principles and independent data. It is purpose- and version-specific. A model that sufficiently answers an interaction question is therefore not automatically qualified for a pediatric prediction or a starting dose estimation without further justification.<\/p>\n
PBPK is a designated subform of modeling and simulation with a physiological body model and its own EMA reporting guideline. General PK\/PD models can describe concentrations and effects empirically or semi-mechanistically without representing organ volumes, blood flow, or enzyme levels as explicit system parameters. The existing entry for modeling-and-simulation is therefore broader in scope.<\/p>\n
In first-in-human planning, PBPK can be used alongside PK\/PD modeling and allometric factors to estimate equivalent human exposure from animal data. However, it does not replace the toxicological assessment of the NOAEL, pharmacological activity, or the relevance of the animal species. The model integrates available information, but the clinical dose decision remains a reasoned comprehensive assessment.<\/p>\n
A PBPK report should clearly distinguish which data were measured, taken from literature sources, or estimated. Particularly for parameters with high uncertainty, it must be justified why the applied range is biologically plausible. This transparency allows predictions to be reproduced and permits verification of whether a conclusion depends on a single, uncertain assumption.<\/p>\n
For interaction questions, PBPK can link the simultaneous administration of an inhibitor or inducer with the expected concentration of the investigational drug. For special populations, changes in physiology or enzyme levels can be simulated. However, such scenarios are only as robust as the underlying system and drug data; they do not automatically replace clinical data if the prediction has not been sufficiently tested.<\/p>\n
For clinical application, the decision the model is intended to support should already be established during scenario planning. An imprecise question easily leads to extensive simulation without clear regulatory benefit. The selected endpoint, such as maximum concentration or area under the curve, must fit the claimed intended use.<\/p>\n
PBPK can structure early dose decisions, interaction scenarios, and questions regarding special populations when direct clinical data are limited. For submission, the model objective, input data, assumptions, scenarios, comparison with observational data, and uncertainties must be documented transparently. Changes to the platform version or drug parameters can influence the prediction and must be evaluated within the respective context.<\/p>\n
Full-service CROs like Mediconomics support PBPK projects through data inventory, definition of the regulatory intended use, coordination of model reports, and linking simulations with protocol and interaction strategies. Clinical pharmacology, biostatistics, and regulatory affairs can then translate the scenarios into reconstructible development decisions.<\/p>\n
Is PBPK just a software simulation?<\/strong><\/p>\n PBPK goes beyond mere software use. The software is the computing platform; the PBPK model consists of the physiological structure, drug parameters, assumptions, and mathematical relationships.<\/p>\n Can a PBPK model replace every clinical study?<\/strong><\/p>\n A model cannot replace clinical trials across the board. It can support defined questions but requires a suitable intended use, sufficient testing of its predictive performance, and an overall scientific evaluation.<\/p>\n Why is the platform version relevant?<\/strong><\/p>\n The EMA assigns the qualification of a PBPK platform to a specific purpose and a specific version because system data and algorithms can influence results.<\/p>\n Physiologically based pharmacokinetic modeling is a mathematical approach that simulates the concentration profiles of a drug in blood and tissues based on physiological, physicochemical, and biochemical parameters. The abbreviation PBPK stands for Physiologically Based Pharmacokinetic Modeling. Unlike general modeling approaches, a PBPK model explicitly represents absorption, distribution, metabolism, and elimination in their interaction with the […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[27],"class_list":["post-8171","glossary","type-glossary","status-publish","hentry","glossary-cat-nichtklinik-pharmakologie"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8171\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=8171"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=8171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n